Beam Therapeutics gave an initial look at the first handful of patients who received its experimental gene-edited treatment ...

Syndax Pharmaceuticals’ $350M deal with Royalty Pharma: The agreement is based on US sales of Niktimvo, Syndax’s graft-versus-host disease ...

Sana Biotech­nol­o­gy is prun­ing its pipeline and head­count for the sec­ond time in around a year to stretch its cash and ...

Despite strong third-quarter revenues, BioNTech has softened its 2024 sales guidance in light of changes to Covid-19 vaccine ...

BioNTech said that its VEGF bispecific sets it apart from competitors because of its mechanism and how it plans to ...

Vertex said it made $2 million in revenue from the first patient who received its sickle cell therapy Casgevy. The commercial launches of Casgevy and bluebird bio’s Lyfgenia have been ...

Nektar Therapeutics is selling off its only manufacturing facility as well as its reagent business to private equity firm Ampersand Capital Partners for $90 million. In the deal, which is ...

Health systems and hospitals across the US have been rolling out artificial intelligence tools to help doctors with administrative tasks like taking notes, coding visits, and responding ...

Plus, news about Disc Medicine, OSE Immunotherapeutics, CrossBridge Bio, Lomond Therapeutics, Relief Therapeutics and Renexxion: Novo Nordisk, Ascendis Pharma ink deal: The Danish drugmaker will pay ...

Well behind Novo Nordisk and Eli Lilly in the obesity race, AstraZeneca came to this year's ObesityWeek with three assets in hand as it hopes to ...

Gene therapy has emerged as a transformative technology, offering life-changing treatments for conditions with few options.

Novo Nordisk’s wildly popular anti-obesity drug Wegovy helped heart disease patients end up in the hospital less often and ...